Clinical Trial Update: Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating subcutaneous immunotherapy for allergic rhinoconjunctivitis caused by Timothy grass pollen (Phleum pratense) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Subcutaneous immunotherapy (Allergen immunotherapy)

Snippet

Sponsor: Roxall Medicina España S.A | Conditions: Allergic Rhinoconjunctivitis | Phase 1 | Status: COMPLETED